⌘K
Loading ticker…
As of 2026-08-24, Fortress Biotech, Inc. (FBIO) has a 3-month relative strength percentile of 61 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 51. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.7%, relative volume 0.83×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
FBIO is in a stage 1 base, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -4.5% / -2.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
FBIO is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $2M notional.
Held by 3 ETFs · $3M across latest filings · largest weight 0.02% (IWC).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $2M | — |
| VXFVanguard Extended Market ETF | 0.00% | $695K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FBIO Jan avg: -4.68% median: -12.71% win: 25% σ: 30.57% n: 4 2022-04-12 → 2026-07-31 | FBIO Feb avg: -4.21% median: -5.89% win: 50% σ: 12.45% n: 4 2022-04-12 → 2026-07-31 | FBIO Mar avg: -4.10% median: -2.24% win: 25% σ: 10.48% n: 4 2022-04-12 → 2026-07-31 | FBIO Apr avg: -5.41% median: -6.46% win: 20% σ: 12.82% n: 5 2022-04-12 → 2026-07-31 | FBIO May avg: -2.57% median: 6.78% win: 60% σ: 22.09% n: 5 2022-04-12 → 2026-07-31 | FBIO Jun avg: 0.07% median: -1.59% win: 40% σ: 6.12% n: 5 2022-04-12 → 2026-07-31 | FBIO Jul avg: 6.02% median: 2.46% win: 80% σ: 9.19% n: 5 2022-04-12 → 2026-07-31 | FBIO Aug avg: 4.13% median: 7.83% win: 50% σ: 33.32% n: 4 2022-04-12 → 2026-07-31 (current) | FBIO Sep avg: -4.59% median: -16.37% win: 25% σ: 32.41% n: 4 2022-04-12 → 2026-07-31 | FBIO Oct avg: -15.40% median: -17.10% win: 25% σ: 38.59% n: 4 2022-04-12 → 2026-07-31 | FBIO Nov avg: 3.14% median: 10.38% win: 75% σ: 15.67% n: 4 2022-04-12 → 2026-07-31 | FBIO Dec avg: 18.98% median: 14.42% win: 50% σ: 26.94% n: 4 2022-04-12 → 2026-07-31 |